As CD74 is the most frequent ROS1 fusion partner and CD74-ROS1 fusion is present in ~44% of NSCLC cases with ROS1 rearrangements,18,19 we also carried out a prespecified analysis of the efficacy of unecritinib for NSCLC cases with CD74-ROS1 fusion. This evidence concerns the gene CD74 and non-small cell lung carcinoma.